IGH is altered in 23.08% of mantle cell lymphoma patients [3].

IGH is an inclusion criterion in 31 clinical trials for mantle cell lymphoma, of which 27 are open and 4 are closed. Of the trials that contain IGH status and mantle cell lymphoma as inclusion criteria, 9 are phase 1 (6 open), 6 are phase 1/phase 2 (6 open), 13 are phase 2 (12 open), and 3 are phase 3 (3 open) [4].

Ibrutinib has evidence of efficacy in patients with IGH mutation in mantle cell lymphoma [4].

Ibrutinib has evidence of efficacy in patients with IGH mutation in mature B-cell lymphoma/leukemia [4].

IGH is altered in 5.98% of multiple myeloma patients [3].

IGH is an inclusion criterion in 40 clinical trials for multiple myeloma, of which 27 are open and 13 are closed. Of the trials that contain IGH status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 11 are phase 1 (5 open), 7 are phase 1/phase 2 (5 open), 19 are phase 2 (14 open), and 2 are phase 3 (2 open) [4].

IGH is an inclusion criterion in 11 clinical trials for plasma cell leukemia, of which 6 are open and 5 are closed. Of the trials that contain IGH status and plasma cell leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 8 are phase 2 (5 open) [4].

IGH is an inclusion criterion in 10 clinical trials for chronic lymphocytic leukemia, of which 8 are open and 2 are closed. Of the trials that contain IGH status and chronic lymphocytic leukemia as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

IGH is altered in 0.37% of acute myeloid leukemia patients [3].

IGH is an inclusion criterion in 7 clinical trials for acute myeloid leukemia, of which 5 are open and 2 are closed. Of the trials that contain IGH status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

IGH is an inclusion criterion in 7 clinical trials for myelodysplastic syndromes, of which 5 are open and 2 are closed. Of the trials that contain IGH status and myelodysplastic syndromes as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

IGH is altered in 16.54% of diffuse large B-cell lymphoma patients [3].

IGH is an inclusion criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain IGH status and diffuse large B-cell lymphoma as inclusion criteria, 4 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [4].

IGH is an inclusion criterion in 6 clinical trials for acute lymphoblastic leukemia, of which 4 are open and 2 are closed. Of the trials that contain IGH status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

IGH is altered in 29.41% of follicular lymphoma patients [3].

IGH is an inclusion criterion in 5 clinical trials for follicular lymphoma, of which 3 are open and 2 are closed. Of the trials that contain IGH status and follicular lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

IGH is altered in 12.73% of non-hodgkin lymphoma patients [3].

IGH is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain IGH status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

IGH is an inclusion criterion in 4 clinical trials for chronic myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain IGH status and chronic myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [4].

IGH is an inclusion criterion in 4 clinical trials for hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain IGH status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

IGH is an inclusion criterion in 4 clinical trials for small lymphocytic lymphoma, of which 2 are open and 2 are closed. Of the trials that contain IGH status and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [4].

IGH is an inclusion criterion in 4 clinical trials for smoldering plasma cell myeloma, of which 3 are open and 1 is closed. Of the trials that contain IGH status and smoldering plasma cell myeloma as inclusion criteria, 3 are phase 2 (2 open) and 1 is phase 3 (1 open) [4].

IGH is an inclusion criterion in 3 clinical trials for marginal zone lymphoma, of which 2 are open and 1 is closed. Of the trials that contain IGH status and marginal zone lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

IGH is altered in 19.26% of B-cell non-hodgkin lymphoma patients [3].

IGH is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

IGH is altered in 10.2% of lymphoma patients [3].

IGH is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IGH status and lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

IGH is altered in 3.4% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].

IGH is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

IGH is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGH status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

IGH is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGH status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

IGH is an inclusion criterion in 2 clinical trials for grade 3b follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IGH status and grade 3b follicular lymphoma as inclusion criteria, 2 are phase 1 (1 open) [4].

IGH is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

IGH is an inclusion criterion in 2 clinical trials for transformed non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

IGH is an inclusion criterion in 2 clinical trials for waldenstrom macroglobulinemia, of which 1 is open and 1 is closed. Of the trials that contain IGH status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

IGH is altered in 5.98% of myeloma patients [3].

IGH is an inclusion criterion in 1 clinical trial for myeloma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

IGH is altered in 0.59% of cancer patients [3].

IGH is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains IGH status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains IGH status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IGH status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains IGH status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IGH status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IGH is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IGH status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IGH status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

IGH is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IGH status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for plasmacytoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and plasmacytoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IGH status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains IGH status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

IGH is an inclusion criterion in 1 clinical trial for T-cell/histiocyte-rich large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IGH status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IGH status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

IGH is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].